Sandra L Spoelstra1, Charles W Given2, Alla Sikorskii3, Constantinos K Coursaris4, Atreyee Majumder3, Tracy DeKoekkoek1, Monica Schueller1, Barbara A Given1. 1. 1 College of Nursing, Michigan State University , East Lansing, Michigan. 2. 2 Department of Family Medicine, Michigan State University , East Lansing, Michigan. 3. 3 Department of Statistics and Probability, Michigan State University , East Lansing, Michigan. 4. 4 Department of Telecommunication, Information Studies, and Media, Michigan State University , East Lansing, Michigan.
Abstract
INTRODUCTION: This multisite, randomized controlled trial assigned 75 adult cancer patients prescribed an oral anticancer agent to either an experimental group that received daily text messages for adherence for 21 days plus usual care or a control group that received usual care. MATERIALS AND METHODS: Measures were administered at baseline, weekly (Weeks 1-8), and at exit (Week 9). A satisfaction survey was conducted following the intervention. Acceptability, feasibility, and satisfaction were examined. Primary outcomes were adherence and symptoms. Secondary outcomes were depressive symptoms, self-efficacy, cognition, physical function, and social support. Mixed or general linear models were used for the analyses comparing trial groups. Effect sizes (ES) were estimated to gauge clinical significance. RESULTS: Regarding acceptability, 57.2% (83 of 145) of eligible patients consented, 88% (n = 37 of 42) receiving text messages read them most or all of the time, and 90% (n = 38) were satisfied. The differences between experimental and control groups' ES were 0.29 for adherence, 0.21 for symptom severity, and 0.21 for symptom interference, and differences were not statistically significant. Furthermore, perceived social support was higher (p = 0.04; ES = 0.54) in the experimental group. CONCLUSIONS: Proof of concept and preliminary efficacy of a mobile health intervention using text messages to promote adherence for patients prescribed oral anticancer agents were demonstrated. Patients accepted and had high satisfaction with the intervention, and adherence improved after the intervention. Text messages show promise. Additional research is needed prior to use in practice.
RCT Entities:
INTRODUCTION: This multisite, randomized controlled trial assigned 75 adult cancerpatients prescribed an oral anticancer agent to either an experimental group that received daily text messages for adherence for 21 days plus usual care or a control group that received usual care. MATERIALS AND METHODS: Measures were administered at baseline, weekly (Weeks 1-8), and at exit (Week 9). A satisfaction survey was conducted following the intervention. Acceptability, feasibility, and satisfaction were examined. Primary outcomes were adherence and symptoms. Secondary outcomes were depressive symptoms, self-efficacy, cognition, physical function, and social support. Mixed or general linear models were used for the analyses comparing trial groups. Effect sizes (ES) were estimated to gauge clinical significance. RESULTS: Regarding acceptability, 57.2% (83 of 145) of eligible patients consented, 88% (n = 37 of 42) receiving text messages read them most or all of the time, and 90% (n = 38) were satisfied. The differences between experimental and control groups' ES were 0.29 for adherence, 0.21 for symptom severity, and 0.21 for symptom interference, and differences were not statistically significant. Furthermore, perceived social support was higher (p = 0.04; ES = 0.54) in the experimental group. CONCLUSIONS: Proof of concept and preliminary efficacy of a mobile health intervention using text messages to promote adherence for patients prescribed oral anticancer agents were demonstrated. Patients accepted and had high satisfaction with the intervention, and adherence improved after the intervention. Text messages show promise. Additional research is needed prior to use in practice.
Entities:
Keywords:
behavioral health; mobile health; technology; teleoncology
Authors: Sandra L Spoelstra; Charles W Given; Alla Sikorskii; Constantinos K Coursaris; Atreyee Majumder; Tracy DeKoekkoek; Monica Schueller; Barbara A Given Journal: J Adv Nurs Date: 2015-06-23 Impact factor: 3.187
Authors: F Bassan; F Peter; B Houbre; M J Brennstuhl; M Costantini; E Speyer; C Tarquinio Journal: Eur J Cancer Care (Engl) Date: 2013-09-15 Impact factor: 2.520
Authors: Sandra L Spoelstra; Charles W Given; Alla Sikorskii; Atreyee Majumder; Monica Schueller; Barbara A Given Journal: Oncol Nurs Forum Date: 2015-01 Impact factor: 2.172
Authors: Barbara Given; Charles W Given; Alla Sikorskii; Sangchoon Jeon; Ruth McCorkle; Victoria Champion; David Decker Journal: J Pain Symptom Manage Date: 2007-12-26 Impact factor: 3.612
Authors: Shoshana M Rosenberg; Keith J Petrie; Annette L Stanton; Lan Ngo; Emma Finnerty; Ann H Partridge Journal: J Natl Cancer Inst Date: 2020-05-01 Impact factor: 13.506
Authors: Sandra L Spoelstra; Alla Sikorskii; Charles W Given; Constantinos K Coursaris; Atreyee Majumder; Monica Schueller; Barbara A Given Journal: Telemed J E Health Date: 2016-03-16 Impact factor: 3.536
Authors: Sarah M Belcher; Emily Mackler; Benyam Muluneh; Pamela K Ginex; Mary K Anderson; Elizabeth Bettencourt; Ryan K DasGupta; Jennifer Elliott; Erica Hall; Michelle Karlin; Diana Kostoff; Victoria K Marshall; Vanessa E Millisor; Maegan Molnar; Susan M Schneider; Janelle Tipton; Susan Yackzan; Kristine B LeFebvre; Kapeena Sivakumaran; Haya Waseem; Rebecca L Morgan Journal: Oncol Nurs Forum Date: 2022-06-17 Impact factor: 1.803
Authors: Irene D Lin; Matthew B Shotts; Ahmad Al-Hader; Kellie Jones Weddle; Richard J Holden; Emily L Mueller; Monica R Macik; Mirian Ramirez; Ephrem Abebe Journal: PLoS One Date: 2022-09-22 Impact factor: 3.752